Skip to content

Randomized controlled clinical trial for secondary prevention strategy of cirrhosis based on NSBB response stratification

Randomized controlled clinical trial for secondary prevention strategy of cirrhosis based on NSBB response stratification

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021212
Enrollment
Unknown
Registered
2019-02-01
Start date
2019-01-22
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhosis with variceal bleeding

Interventions

Group 1:combination of NSBB and endoscopic treatment

Sponsors

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. cirrhosis with no response of NSBB for secondary prevention; 2. Aged 18-75 years old; 3. diagnosis with cirrhosis (based on a liver biopsy or on clear clinical data with compatible findings upon imaging); 4. presence of esophageal varices or gastric varices by a recent upper endoscopy procedure; 5. History of esophageal varices bleeding; 6. provision of informed consent before participating in the study.

Exclusion criteria

Exclusion criteria: 1. baseline HVPG <12 mmHg; 2. end-stage cirrhosis (with refractory ascites, hepatorenal syndrome and a score=10 in the Child-Pugh scoring system); 3. contraindications to NSBBs (asthma, severe chronic obstructive lung disease, sinus bradycardia, II-III degree atrioventricular block); 4. taking drugs that affect the metabolism and absorption of non-selective beta blockers in the body at the same time; 5. also use other drugs that reduce portal pressure; 6. liver cancer, portal vein thrombosis or cavernous transformation of the portal vein; 7. Severe heart, lung, liver, kidney dysfunction, or severe bleeding disorders or local/systemic infections, hypothyroidism, Raynaud's syndrome, peripheral vascular disease, etc.; 8. Women who are planning to become pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Rebileeding Rate;

Countries

China

Contacts

Public ContactYuZheng Zhuge

Gulou Hospital Affiliated to Nanjing University Medical College

yuzheng9111963@aliyun.com+86 15996289206

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026